This is a proposal developed within the community as an important first step in formalizing standards in reporting the production and properties of protein binding reagents, such as antibodies, developed and sold for the identification and detection of specific proteins present in biological samples. It defines a checklist of required information, intended for use by producers of affinity reagents, qualitycontrol laboratories, users and databases. We envision that both commercial and freely available affinity reagents, as well as published studies using these reagents, could include a MIAPAR-compliant document describing the product’s properties with every available binding partner. This would enable the user or reader to make a fully infor...
Report: A community standard format for the representation of protein affinity reagent
International audienceThe EU ProteomeBinders coordination action helped define community standards f...
On the basis of discussions with representatives from all sectors of the cancer research community, ...
This is a proposal developed within the community as an important first step in formalizing standard...
We wish to alert your readers to MIAPAR, the minimum information about a protein affinity reagent. T...
International audienceThis is a proposal developed within the community as an important first step i...
The information required for the description of affinity reagent/target pairs can be divided into: o...
Is specificity an important issue regarding affinity reagents? What about the validation of affinity...
Protein affinity reagents (PARs), most commonly antibodies, are essential reagents for protein chara...
Protein affinity reagents (PARs), most commonly antibodies, are essential reagents for protein chara...
Protein affinity reagents (PARs), most commonly antibodies, are essential reagents for protein chara...
Essential to the ambition of characterising fully the human proteome are systematic and com-prehensi...
Protein affinity reagents (PARs), most commonly antibod-ies, are essential reagents for protein char...
Immunogenicity assays are required to measure antidrug antibodies that are generated against biother...
The newly launched Affinity Binder Knockdown Initiative encourages antibody suppliers and users to j...
Report: A community standard format for the representation of protein affinity reagent
International audienceThe EU ProteomeBinders coordination action helped define community standards f...
On the basis of discussions with representatives from all sectors of the cancer research community, ...
This is a proposal developed within the community as an important first step in formalizing standard...
We wish to alert your readers to MIAPAR, the minimum information about a protein affinity reagent. T...
International audienceThis is a proposal developed within the community as an important first step i...
The information required for the description of affinity reagent/target pairs can be divided into: o...
Is specificity an important issue regarding affinity reagents? What about the validation of affinity...
Protein affinity reagents (PARs), most commonly antibodies, are essential reagents for protein chara...
Protein affinity reagents (PARs), most commonly antibodies, are essential reagents for protein chara...
Protein affinity reagents (PARs), most commonly antibodies, are essential reagents for protein chara...
Essential to the ambition of characterising fully the human proteome are systematic and com-prehensi...
Protein affinity reagents (PARs), most commonly antibod-ies, are essential reagents for protein char...
Immunogenicity assays are required to measure antidrug antibodies that are generated against biother...
The newly launched Affinity Binder Knockdown Initiative encourages antibody suppliers and users to j...
Report: A community standard format for the representation of protein affinity reagent
International audienceThe EU ProteomeBinders coordination action helped define community standards f...
On the basis of discussions with representatives from all sectors of the cancer research community, ...